MARKET DYNAMICS

Amazon recently announced the launch of their online pharmacy, allowing customersto purchase generic medications, including insulin and inhalers, directly through itsplatform. Prime members without insurance can receive discounted medications, andall members will have their medications delivered directly to their doorstep withoutthe need for an in-person pharmacy visit. Amazon first ventured into the sector withthe $750 million PillPack acquisition in 2018, a startup focused on direct-to-consumerprescription drugs, which is likely to play a large role in this larger market play.

OPHTHALMOLOGY

Glenmark Pharmaceuticals has launched ageneric version of Travoprost OphthalmicSolution USP, 0.004%, in the U.S., which isbioequivalent to the Sandoz brand TravatanZ. Glenmark's portfolio now includes 200products in the U.S. and 51 ANDAsubmissions awaiting FDA approval,highlighting their commitment to expandingtheir market presence and product offerings.

REGULATORY ACTION

Barriers to entry in the generics market are rising, driven byincreased patent-related legal action as manufacturers defendexclusivity against competitors. Pfizer recently sued Sandoz,alleging its generic version of Inlyta, a kidney cancer treatment,infringes on a patent for crystalline forms of axitinib. Roche filed a similar lawsuit against Natco Pharma and ZydusLifesciences, challenging their FDA bids for generic versions ofEvrysdi, the only noninvasive treatment for spinal muscularatrophy. Incyte also recently secured an injunction blocking SunPharma's generic JAK inhibitor Leqselvi, safeguarding Jakafi'smarket share until its patent expires in late 2026."

MARKET DYNAMICS

The European Commission has fined Teva, the world'slargest generic drugmaker, €462.6 million for abusingits dominant position by artificially extending the patentprotection of its multiple sclerosis drug Copaxone andspreading misleading information about a competingproduct. Teva plans to appeal the decision, but theCommission asserts that enforcing competition laws inthe pharmaceutical sector is essential for keeping drugsaffordable, preserving treatment choices, and benefitingEU patients and national healthcare systems.

ANTIVIRALS

Gilead Sciences has reached royalty-free voluntarylicensing agreements with six generic manufacturers toproduce and distribute generic versions of lenacapavir,an investigational HIV prevention drug, in 120 resourcelimited countries primarily across Africa and Asia. Theseagreements closely follow the release of results fromthe PURPOSE trials, which demonstrated the drug’ssuperiority over current standard PrEP medications.Regulatory filings are expected to begin by the end of2024, and Gilead plans to provide lenacapavir at noprofit until the generic manufacturers can fully meetmarket demand.

DIABETES & METABOLIC DISORDERS

As the demand for GLP-1 agonist treatments continues tosurge, several generic alternatives are nearing approval toenter markets across the globe. In the US, AmnealPharmaceuticals gained FDA approval for exenatide, one ofthe first generic GLP-1 injectables, while telehealthprovider Hims & Hers Health plans to offer a genericversion of liraglutide (Victoza), expanding its existing GLP-1agonist offerings. In the UK, The British GenericManufacturers Association announced that at least fourcompanies are poised to receive authorizations for genericweight loss drugs like liraglutide (formerly Saxenda andVictoza) to address UK supply shortages.